Literature DB >> 15222281

Predictable changes in left ventricular mass and function during ten years after valve replacement for aortic stenosis.

Ole Lund1, Mogens Erlandsen, Inge Dørup, Kristian Emmertsen, Christian Flø, Finn T Jensen.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Left ventricular (LV) hypertrophy is the underlying basis for longevity after aortic valve replacement (AVR) for aortic stenosis (AS). However, a detailed account of changes in LV mass and function in the long term after AVR and identification of the determinants of such changes have not yet been presented.
METHODS: Ninety-one unselected consecutive adult patients with AS underwent AVR and were followed up to 10 years, at which time 41 survivors without new mitral disease underwent repeat measurement of LV mass index (LVMi), ejection fraction (LVEF), fast filling fraction (LVFFF), and end-diastolic volume index (LVEDVi). A subgroup comprising 49 patients was also assessed at eight days, three months, and 1.5 years postoperatively. All measurements were analyzed in a longitudinal regression model for repeated measures.
RESULTS: LVMi fell from 202 +/- 58 g/m2 (n = 91) via 150 +/- 45 g/m2 (n = 39) at 1.5 years to 139 +/- 40 g/m2 (n = 41) at 10 years in all patients, and to 124 +/- 31 g/m2 (n = 29) in non-hypertensive patients. The LVMi falls were paralleled by improvements in LVEF and LVEDVi. LVFFF was not correlated to LVMi before the 10-year study. The longitudinal model indicated progressive reduction of LVMi to 1.5 years, but no change thereafter. The predictor variables were preoperative LVMi and end-systolic dimension index (high values of both related to high postoperative LVMi), hypertension, and male gender. The model for LVEF indicated a rapid increase to three months, followed by a slight decrease to 1.5 years and further to 10 years, predicted by preoperative LVEF and LVFFF. LVFFF fell sharply by three months, had recovered somewhat at 1.5 years and fully at 10 years, positively related to preoperative LVFFF and inversely to end-systolic chamber radius:wall thickness ration and small-sized prosthetic valves. LVEDVi converged from extreme values over time predicted by preoperative LVEF, but rose with hypertension and coronary artery disease. Hemodynamic function of the prosthetic aortic valve at any of the measurement times had no impact.
CONCLUSION: Changes in LV mass and function up to 10 years after AVR for AS were highly predictable. Poorer outcomes were related to preoperative excessive hypertrophy and indices of underlying irreversible myocardial disease and further compromised by hypertension and, to a lesser extent, coronary artery disease. The hemodynamic function of the aortic prosthetic valve did not seem to play a role.

Entities:  

Mesh:

Year:  2004        PMID: 15222281

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  10 in total

Review 1.  The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors.

Authors:  John Chambers
Journal:  Heart       Date:  2006-03       Impact factor: 5.994

2.  Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis.

Authors:  Jocelyn M Beach; Tomislav Mihaljevic; Lars G Svensson; Jeevanantham Rajeswaran; Thomas Marwick; Brian Griffin; Douglas R Johnston; Joseph F Sabik; Eugene H Blackstone
Journal:  J Am Coll Cardiol       Date:  2013-02-26       Impact factor: 24.094

3.  Risk stratification and management of aortic stenosis with concomitant left ventricular dysfunction.

Authors:  Matthew L Steinhauser; Peter H Stone
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-12

4.  Improvement in left ventricular function assessed by tissue Doppler imaging after aortic valve replacement for severe aortic stenosis.

Authors:  Chih-Chiang Nieh; Alvin Yeng-Hok Teo; Wern Miin Soo; Glenn K Lee; Devinder Singh; Kian-Keong Poh
Journal:  Singapore Med J       Date:  2015-12       Impact factor: 1.858

5.  Left ventricular mass regression following implantation of MIRA bileaflet valves in patients with severe aortic stenosis.

Authors:  Stefan Toggweiler; Michel Zuber; Katharina Gerber; Reinhard Schläpfer; Paul Erne; Peter Stulz
Journal:  Heart Vessels       Date:  2009-01-23       Impact factor: 2.037

6.  Anatomical and functional changes after aortic valve replacement with different sizes of mechanical valves.

Authors:  Gokhan Ilhan; Sahin Bozok; Berkan Ozpak; Hakan Kara; Serkan Yazman; Serdar Bayrak; Ibrahim Ozsoyler; Ali Gurbuz
Journal:  Cardiovasc J Afr       Date:  2018-07-17       Impact factor: 0.802

7.  Impact of Valvuloarterial Impedance on Concentric Remodeling in Aortic Stenosis and Its Regression after Valve Replacement.

Authors:  Jeong Yoon Jang; Jeong-Sook Seo; Byung Joo Sun; Dae-Hee Kim; Jong-Min Song; Duk-Hyun Kang; Jae-Kwan Song
Journal:  J Cardiovasc Ultrasound       Date:  2016-09-26

8.  Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study.

Authors:  Ignacio J Amat-Santos; Pablo Catalá; Felipe Diez Del Hoyo; Jose A Fernandez-Diaz; Juan H Alonso-Briales; María Del Trigo; Ander Regueiro; Pablo Juan-Salvadores; Vicenç Serra; Enrique Gutierrez-Ibanes; Antonio J Muñoz-García; Luis Nombela-Franco; Manel Sabate; Victor A Jimenez-Diaz; Bruno García Del Blanco; Javier López; Luis H Varela-Falcón; Teresa Sevilla; Roman Arnold; Ana Revilla; J Alberto San Roman
Journal:  BMJ Open       Date:  2018-02-13       Impact factor: 2.692

9.  Surgical outcomes and post-operative changes in patients with significant aortic stenosis and severe left ventricle dysfunction.

Authors:  Sung-Ho Jung; Jae Won Lee; Hyung Gon Je; Suk Jung Choo; Cheol Hyun Chung; Hyun Song
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

10.  Renin-Angiotensin System Blockade in Aortic Stenosis: Implications Before and After Aortic Valve Replacement.

Authors:  Sachin S Goel; Neal S Kleiman; William A Zoghbi; Michael J Reardon; Samir R Kapadia
Journal:  J Am Heart Assoc       Date:  2020-09-06       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.